We assume that such dsDNA edges will then facilitate of an oligonucleotide) to recognize the designated sethe proximal strand invasion of corresponding pcODNs quence within linear DNA duplexes. Note that although (structure III in Figure 1B ), similar to their binding at the various DNA binding ligands can be used for this purvery end of the dsDNA (see structure I in the same pose [4], targeting of dsDNA with oligonucleotides is figure) . Consequently, the internal dsDNA sites of an advantageous for many applications. Accordingly, sevarbitrary sequence could be sequence specifically tareral approaches have been developed to this end.
Introduction
Our design employs pseudocomplementary (pc) PNAs We assume that such dsDNA edges will then facilitate of an oligonucleotide) to recognize the designated sethe proximal strand invasion of corresponding pcODNs quence within linear DNA duplexes. Note that although (structure III in Figure 1B ), similar to their binding at the various DNA binding ligands can be used for this purvery end of the dsDNA (see structure I in the same pose [4], targeting of dsDNA with oligonucleotides is figure) . Consequently, the internal dsDNA sites of an advantageous for many applications. Accordingly, sevarbitrary sequence could be sequence specifically tareral approaches have been developed to this end.
geted by oligonucleotide probes. While this design is One of them utilizes triplexes formed via Hoogsteen rather simple and straightforward, its workability is not and Hoogsteen-like pairing of purine or pyrimidine oligoobvious at the outset. nucleotides with a corresponding dsDNA site [4-6].
First The results with protein tagging and primer extension illustrate that our approach can be used for sequencefragment in the presence of streptavidin, demonstrates that DNA can be selectively tagged, via the PNA-medispecific manipulation with basically intact duplex DNA. We anticipate that it may be employed for nondenaturated binding of oligonucleotide, with a protein when biotinylated pcODN is used (see Figure 2 , lane 3 as a ing dsDNA sequencing, labeling, and isolation, hence offering numerous subsequent applications for DNA negative control without pcPNA). 
